1.60
+0(+0.00%)
Currency In USD
Address
1055 Westlakes Drive
Berwyn, PA 19312
United States of America
Phone
610 727 3913
Website
Sector
Healthcare
Industry
Biotechnology
Employees
6
First IPO Date
January 29, 2020
| Name | Title | Pay | Year Born |
| Dr. Maria L. Maccecchini Ph.D. | Founder, Chief Executive Officer, President & Executive Director | 681,200 | 1951 |
| Ms. Hilda Maibach | Senior Vice President of Statistics | 0 | N/A |
| Mr. Mark K. White | Chief Business Officer & Director | 0 | 1956 |
| Dr. Cheng Fang Ph.D. | Senior Vice President of Research & Development | 0 | N/A |
| Ms. Melissa Gaines | Senior Vice President of Clinical Operations | 0 | N/A |
| Ms. Eve M. Damiano M.S., RAC | Senior Vice President of Regulatory Operations | 0 | N/A |
| Mr. William Vincent Fricker CPA, Ph.D. | Chief Financial Officer | 0 | 1965 |
| Mr. Blake Jensen | Head of Quality | 0 | N/A |
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.